Sequoia China announces the completion of the acquisition of global business for Moxifloxacin

36Kr learned that Sequoia China announced that it has officially completed the global acquisition of the core product of fluoroquinolone antibiotics, moxifloxacin (brand name: Avelox®), along with related businesses and assets on February 3rd. It has established an innovative biopharmaceutical company, Hangzhou ShanZe Biopharmaceutical Co., Ltd., focused on anti-infection and respiratory fields, with its parent company Ascenda Pte. Ltd. responsible for the operation of this business. According to the agreement, ShanZe Biopharmaceutical and its parent company Ascenda Pte. Ltd. have acquired specific assets of Avelox® globally, including drug registration certificates, intellectual property, and business contracts in relevant countries and regions